

Linavonkibart Biosimilar - Research Grade

Product Code: ICH5253

More Information

Species Reactivity: Human

Target: TGFB1

Concentration: >1mg/ml

Isotype: Human IgG4 - kappa

Host: CHO Cells

product name H2: Linavonkibart Biosimilar - Research Grade

Antibodies against the same target: [Fresolimumab Biosimilar - Research Grade \(ICH5077\)](#), [Metelimumab Biosimilar - Research Grade \(ICH5257\)](#), [Cirevetmab Biosimilar - Research Grade \(ICH5440\)](#), [Nisevokitug Biosimilar - Research Grade \(ICH5713\)](#)

Sequence: <https://www.imgt.org/mAb-DB/>

Buffer: ICH3002

UniProt: P01137

Shipping Conditions: Blue ice

background: This is a research-grade, unconjugated recombinant analog of linavonkibart, a human IgG4-kappa antibody directed against transforming growth factor beta 1 (TGF-beta 1, TGFB1; UniProt P01137). It is supplied strictly for research use only and is not the clinical therapeutic; it is not intended for human or veterinary use. The molecule reproduces the antigen-binding specificity of the originator, allowing investigators to interrogate TGF-beta 1 biology in controlled experimental systems. Typical applications include in-vitro ligand neutralisation, receptor-binding and blocking assays, use as a positive isotype-matched

control for IgG4 formats, and as a reference standard in ADCC/ADC and antibody-engineering workflows. It is offered in bulk milligram-to-gram quantities with low-endotoxin grades (research grade 1 EU/mg; ultra-low 0.5 EU/mg) to support cell-based and preclinical work where endotoxin would confound readouts. Because it is furnished as a defined, reproducible reagent, it is well suited to standardising assays across experiments and laboratories, benchmarking biosimilar candidates, and building assays around a well-characterised anti-TGF-beta 1 binder without reliance on scarce clinical material. Transforming growth factor beta 1 (TGFB1) is a secreted, disulphide-linked homodimeric cytokine and the prototypic member of the TGF-beta superfamily. It is produced as a latent complex in which the mature growth factor remains non-covalently associated with its latency-associated peptide; activation by integrins, proteases, or mechanical force liberates active ligand. Active TGF-beta 1 signals through the type II (TGFB2) and type I (TGFB1/ALK5) serine-threonine kinase receptors, driving SMAD2/3 phosphorylation and complex formation with SMAD4, alongside non-canonical MAPK and PI3K pathways. Biologically, TGF-beta 1 is a master regulator of cell proliferation, differentiation, extracellular-matrix deposition, epithelial-mesenchymal transition, and immune tolerance, including regulatory T-cell induction. Dysregulated TGF-beta 1 signalling contributes to tissue fibrosis, and to tumour immune evasion and metastasis, making it a target of intense therapeutic and mechanistic research interest.

Other names: Transforming growth factor beta-1 proprotein, TGFB

Specificity: Detects human TGFB1

Purification Method: This monoclonal antibody was purified using Protein A

Formulation: Sterile, preservative-free, solution in PBS. BSA and Azide free.

Purity: >95% by SDS-PAGE

Endotoxin: ≤ 1.0 EU/mg as determined by the LAL method

Storage: This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Applications: Functional Assays

Application Notes: This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.



Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Delivery Time: 4 weeks